Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

DMTK - DermTech Inc


Close
0.094
-0.012   -12.766%

Share volume: 3,662,379
Last Updated: Wed 26 Jun 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$0.11
-0.01
-11.32%
This ticker is disabled and data are no longer maintained and up to date.
Fundamental analysis
12%
Profitability 7%
Dept financing 9%
Liquidity 75%
Performance 3%
Company vs Stock growth
vs
Performance
5 Days
0   0%
1 Month
0   0%
3 Months
0   0%
6 Months
0   0%
1 Year
0   0%
2 Year
0   0%
Key data
Stock price
$0.09
P/E Ratio 
0.00
DAY RANGE
$0.09 - $0.10
EPS 
-$2.66
52 WEEK RANGE
$0.00 - $0.00
52 WEEK CHANGE
$0.00
MARKET CAP 
0.000
YIELD 
N/A
SHARES OUTSTANDING 
35.262 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$0
AVERAGE 30 VOLUME 
$0
Company detail
CEO:
Region: US
Website: dermtech.com
Employees: 0
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

dermtech is a molecular diagnostic dermatology company focused on developing non-invasive gene expression tests to aid the clinical diagnosis of skin cancer and other skin conditions. dermtech operates a clia (clinical laboratory improvement amendments) licensed laboratory located at the company’s la jolla, ca headquarters. dermtech’s technology allows for the analysis of skin biopsy samples collected non-invasively using an adhesive patch. current dermatologic diagnosis is primarily based on subjective visual pattern recognition that is prone to error and results in a substantial number of unnecessary surgical procedures. dermtech’s pigmented lesion assay (pla) provides physicians with a non-invasive option for the biopsy of clinically atypical pigmented lesions using an adhesive patch rather than a scalpel. dermtech provides highly accurate, objective information to the physician to improve patient care and comfort and reduce costs. the pla is used for the detection of melanoma in at

Recent news